Interleukin‐13 promoter gene polymorphism ‐1112C/T is associated with the systemic form of mastocytosis
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Mastocytosis is a heterogenous disease involving mast cells (MC) and their progenitors. Cutaneous and systemic variants of the disease have been reported. In contrast to cutaneous mastocytosis (CM), patients with systemic mastocytosis (SM) are at risk to develop disease progression or a nonMC‐lineage haematopoietic neoplasm. Little is known, however, about factors predisposing for the development of SM. One factor may be cytokine regulation of MC progenitors. Methods: We examined the role of the interleukin‐13 (IL‐13) promoter gene polymorphism ‐1112C/T, known to be associated with increased transcription, in mastocytosis using allele‐specific polymerase chain reaction method. Serum tryptase and IL‐13 levels were determined by immunoassay, and expression of the IL‐13 receptor in neoplastic MC by reverse transcription‐polymerase chain reaction and flow cytometry. Results: The frequency of the ‐1112T allele of the IL‐13 promoter was significantly higher in patients with SM compared with CM (P < 0.008) and in mastocytosis patients compared with healthy controls (P < 0.0001). Correspondingly, the polymorphism was found to correlate with an elevated serum tryptase level (P = 0.004) and with adult‐onset of the disease (P < 0.0015), both of which are almost invariably associated with SM. Serum IL‐13 levels were also higher in SM patients compared with CM (P = 0.011), and higher in CT‐ than in CC carriers (P < 0.05). Finally, we were able to show that neoplastic human MC display IL‐13 receptors and grow better in IL‐13‐containing medium. Conclusions: The ‐1112C/T IL‐13 gene polymorphism and the resulting ‘hypertranscription’ may predispose for the development of SM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis
Schwartz, L. B., Metcalfe, D. D., Miller, J. S., Earl, H., & Sullivan, T. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706253162603 · Cited by 784 · cited 1×
“Serum tryptase levels were higher in patients with SM compared with patients with CM, confirming the previous literature (5, 6, 32, 33).”
ResultValent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 20×
“In our experiments, we found that HMC-1 cells, a cell line derived from a patient with MCL, express the IL-13 R as well as the -1112T polymorphism C/T.”
BackgroundMethodResultInfluentialSelf-citationEstablishment of an immature mast cell line from a patient with mast cell leukemia
Butterfield, J. H., Weiler, D., Dewald, G., & Gleich, G. J. (1988) · Leukemia Research · doi:10.1016/0145-2126(88)90050-1 · Cited by 737
Schwartz, L. B., Sakai, K., Bradford, T. R., Ren, S., Zweiman, B., Worobec, A. S., & Metcalfe, D. D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118337 · Cited by 371 · cited 1×
“Serum tryptase levels were higher in patients with SM compared with patients with CM, confirming the previous literature (5, 6, 32, 33).”
ResultAkin, C., Scott, L. M., Kocabas, C. N., Kushnir-Sukhov, N., Brittain, E., Noel, P., & Metcalfe, D. D. (2007) · Blood · doi:10.1182/blood-2006-06-028100 · Cited by 240 · cited 5×
“Nine adult patients had CM, and two adult patients (2%) with typical mediator-related symptoms were found to fulfil only two minor SM criteria, a condition recently described as monoclonal MC activation syndrome (MMAS) (6, 28, 29).”
BackgroundInfluentialSonneck, K., Florian, S., Müllauer, L., Wimazal, F., Födinger, M., Sperr, W. R., & Valent, P. (2007) · International Archives of Allergy and Immunology · doi:10.1159/000096442 · Cited by 129 · cited 5×
“Nine adult patients had CM, and two adult patients (2%) with typical mediator-related symptoms were found to fulfil only two minor SM criteria, a condition recently described as monoclonal MC activation syndrome (MMAS) (6, 28, 29).”
BackgroundSelf-citation
Cited by
Valent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Self-citationValent, P., Escribano, L., Broesby‐Olsen, S., Hartmann, K., Grattan, C., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, J. N. G., Kristensen, T., et al. (2014) · Allergy · doi:10.1111/all.12436 · Cited by 174
Self-citationThe genetic basis of mast cell activation disease - looking through a glass darkly
Molderings, G. J. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.09.001 · Cited by 50
Haenisch, B., Nöthen, M. M., & Molderings, G. J. (2012) · Immunology · doi:10.1111/j.1365-2567.2012.03627.x · Cited by 48
Metadata
- Authors
- Nedoszytko, B., Niedoszytko, M., Lange, M., Van Doormaal, J., Gleń, J., Zabłotna, M., Renke, J., Vales, A., Buljubasic, F., Jassem, E., Roszkiewicz, J., & Valent, P.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2009-01-21
- Volume
- 64
- Issue
- 2
- Pages
- 287-294
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2144267170
- Cited by
- 35
- References
- 6
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin‐13 promoter gene polymorphism ‐1112C/T is associated with the systemic form of mastocytosis. https://app.cochat.ai/papers/10.1111/j.1398-9995.2008.01827.x
- The paper
- Nedoszytko, B., Niedoszytko, M., Lange, M., Van Doormaal, J., Gleń, J., Zabłotna, M., Renke, J., Vales, A., Buljubasic, F., Jassem, E., Roszkiewicz, J., & Valent, P. (2009). Interleukin‐13 promoter gene polymorphism ‐1112C/T is associated with the systemic form of mastocytosis. Allergy. https://doi.org/10.1111/j.1398-9995.2008.01827.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.